Top

Reproductive Biology and Endocrinology

Published in:

Open Access 01-12-2018 | Research

Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice

Authors: Bo Liang, Ling Wu, Hui Xu, Chun Wai Cheung, Wen Ying Fung, Sze Wai Wong, Chi Chiu Wang

Published in: Reproductive Biology and Endocrinology | Issue 1/2018

Abstract

Background

Current medical treatments for endometriosis are very limited. Progestin and selective progesterone receptor modulators (SPRM) are developed but their efficacy, safety, mechanism and recurrence in endometriosis are not fully studied.

Methods

In order to compare therapeutic, side effects and therapeutic actions of Esmya, Duphaston and Dienogest in endometriosis. Experimental endometriosis was induced by either intraperitoneal or subcutaneous mouse endometrium transplantation. Lesion size, weight and histology at the end of intervention were compared. Expression of related markers in the endometriotic lesions were examined. Body, uterus and ovary weights, endometrial glands and thickness (ETI), and follicle count were measured. For recurrent study, lesion growth before and after intervention was monitored.

Results

After Esmya, Duphaston, Dienogest treatment, lesion size and weight were significantly decreased. Proliferation Pcna expression was significantly decreased in all groups, but proliferation cells were significantly decreased only in Duphaston group. Apoptosis Mapk1 expression and TUNEL-positive cells were significantly increased in Duphaston group. Adhesion Mmp2 and Itgavβ3 expression were significantly increased in Esmya group. Plau, Hif1α and Vegfa expression, peritoneal fluid PGE2 levels, and ERα and ERβ expression were not affected; while PR expression was significantly lower in all groups. Endometrial gland count in uterus was significantly increased in Dienogest group, ETI was significantly decreased in Duphaston group, and AFC were significantly increased in Esmya group. Upon treatment cessation, lesion growth rebound quickly in Dienogest and Duphaston groups, but slowly in Esmya group.

Conclusion

Esmya, Duphaston and Dienogest are effective anti-endometriosis drugs targeting proliferation, apoptosis and adhesion. Esmya, Duphaston and Dienogest are all well tolerable, although endometrial glandular hyperplasia was found in Dienogest, endometrial atrophy in Duphaston, follicle accumulation in Esmya.

Available only for authorised users

Garcia-Velasco JA, Somigliana E. Management of endometriomas in women requiring IVF: to touch or not to touch. Hum Reprod. 2009;24:496–501.CrossRefPubMed

Meuleman C, Vandenabeele B, Fieuws S, Spiessens C, Timmerman D, D'Hooghe T. High prevalence of endometriosis in infertile women with normal ovulation and normospermic partners. Fertil Steril. 2009;92:68–74.CrossRefPubMed

Kitawaki J, Kado N, Ishihara H, Koshiba H, Kitaoka Y, Honjo H. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol. 2002;83:149–55.CrossRefPubMed

Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14:422–69.CrossRef

Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, Andersson S, Johns A, Meng L, Putman M, Carr B, Bulun SE. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab. 1998;83:4474–80.PubMed

van der Linden PJ. Theories on the pathogenesis of endometriosis. Human Reprod (Oxford, England). 1996;11(Suppl 3):53–65.CrossRef

Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med. 2001;345:266–75.CrossRefPubMed

Fuldeore MJ, Soliman AM. Prevalence and symptomatic burden of diagnosed endometriosis in the United States: National Estimates from a cross-sectional survey of 59,411 women. Gynecol Obstet Investig. 2016;

De Graaff AA, D'Hooghe TM, GAJ D, Dirksen CD, Hummelshoj L, Simoens S, Bokor A, Brandes I, Brodszky V, Canis M, et al. The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. Hum Reprod. 2013;28:2677–85.CrossRefPubMed

10.

Fagervold B, Jenssen M, Hummelshoj L, Moen MH. Life after a diagnosis with endometriosis - a 15 years follow-up study. Acta Obstet Gynecol Scand. 2009;88:914–9.CrossRefPubMed

11.

Dunselman GaJ, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, Heikinheimo O, Horne AW, Kiesel L, Nap A, et al: ESHRE guideline: management of women with endometriosis. Hum Reprod 2014, 29:400–412.

12.

Bateman J, Bougie O, Singh S, Islam S. Histomorphological changes in endometriosis in a patient treated with ulipristal: a case report. Pathol Res Pract. 2017;213:79–81.CrossRefPubMed

13.

Cornillie FJ, Puttemans P, Brosens IA. Histology and ultrastructure of human endometriotic tissues treated with dydrogesterone (Duphaston). Eur J Obstet Gynecol Reprod Biol. 1987;26:39–55.CrossRefPubMed

14.

Schindler AE, Henkel A, Moore C, Oettel M. Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis. Arch Gynecol Obstet. 2009;282:507–14.CrossRefPubMed

15.

Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–20.CrossRefPubMed

16.

Courtoy GE, Donnez J, Marbaix E, Dolmans M-M. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015;104:426–34. e421CrossRefPubMed

17.

Esber N, Le Billan F, Resche-Rigon M, Loosfelt H, Lombès M, Chabbert-Buffet N. Ulipristal acetate inhibits progesterone receptor isoform A-mediated human breast Cancer proliferation and BCl2-L1 expression. PLoS One. 2015;10:e0140795.CrossRefPubMedPubMedCentral

18.

Mansour D. Use of the new progestogens in contraception and gynaecology. Obstet Gynaecol. 2006;8:229–34.

19.

Overton CE, Lindsay PC, Johal B, Collins SA, Siddle NC, Shaw RW, Barlow DH. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertil Steril. 1994;62:701–7.CrossRefPubMed

20.

Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107:533–6.CrossRefPubMed

21.

Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril. 1997;68:393–401.CrossRefPubMed

22.

Okada H, Nakajima T, Yoshimura T, Yasuda K, Kanzaki H. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol Hum Reprod. 2001;7:341–7.CrossRefPubMed

23.

Laschke MW, Menger MD. Anti-angiogenic treatment strategies for the therapy of endometriosis. Hum Reprod Update. 2012;18:682–702.CrossRefPubMed

24.

Makabe T, Koga K, Miyashita M, Takeuchi A, Sue F, Taguchi A, Urata Y, Izumi G, Takamura M, Harada M, et al. Drospirenone reduces inflammatory cytokines, vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) expression in human endometriotic stromal cells. J Reprod Immunol. 2017;119:44–8.CrossRefPubMed

25.

Nakamura M, Katsuki Y, Shibutani Y, Oikawa T. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol. 1999;386:33–40.CrossRefPubMed

26.

Tsuchiya T, Katagiri Y, Maemura T, Hayata E, Fukuda Y, Kitamura M, Morita M. Preoperative dienogest to improve the surgical field of view in resectoscopic surgery. Gynecol Minim Invasive Ther. 2016;5:16–9.CrossRef

27.

Pelch KE, Sharpe-Timms KL, Nagel SC. Mouse model of surgically-induced endometriosis by auto-transplantation of uterine tissue. J Vis Exp. 2012:e3396.

28.

Bacci M, Capobianco A, Monno A, Cottone L, Di Puppo F, Camisa B, Mariani M, Brignole C, Ponzoni M, Ferrari S, et al. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. Am J Pathol. 2009;175:547–56.CrossRefPubMedPubMedCentral

29.

Aoki D, Katsuki Y, Shimizu A, Kakinuma C, Nozawa S. Successful heterotransplantation of human endometrium in SCID mice. Obstet Gynecol. 1994;83:220–8.PubMed

30.

Wang CC, Xu H, GCW M, Zhang T, Chu KO, Chu CY, JTY C, Li G, He YX, Qin L, et al. Prodrug of green tea epigallocatechin-3-gallate (pro-EGCG) as a potent anti-angiogenesis agent for endometriosis in mice. Angiogenesis. 2013;16:59–69.CrossRefPubMed

31.

Xu H, Lui WT, Chu CY, Ng PS, Wang CC, Rogers MS. Anti-angiogenic effects of green tea catechin on an experimental endometriosis mouse model. Hum Reprod. 2009;24:608–18.CrossRefPubMed

32.

Rockville. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. In: Center for Drug Evaluation and Research (CDER); 2005.

33.

Oliveira CR, Salvatori R, Nobrega LM, Carvalho EO, Menezes M, Farias CT, Britto AV, Pereira RM, Aguiar-Oliveira MH. Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene. Clin Endocrinol. 2008;69:153–8.CrossRef

34.

Cardiff RD, Miller CH, Munn RJ: Manual hematoxylin and eosin staining of mouse tissue sections. Cold Spring Harb Protoc 2014, 2014:pdb.prot073411.

35.

Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med. 1999;31:34–45.CrossRefPubMed

36.

Rabbani SA. Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo. 1998;12:135–42.PubMed

37.

Sheppard D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev. 2005;24:395–402.CrossRefPubMed

38.

Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI, for the T, Angiogenesis Research G. Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer. 2002;95:1055–63.CrossRefPubMed

39.

Goteri G, Lucarini G, Montik N, Zizzi A, Stramazzotti D, Fabris G, Tranquilli AL, Ciavattini A. Expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor-1alpha (HIF-1alpha), and microvessel density in endometrial tissue in women with adenomyosis. Int J Gynecol Pathol. 2009;28:157–63.CrossRefPubMed

40.

Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001;12:73–90.CrossRefPubMed

41.

Schwartz SA, Hernandez A, Mark Evers B. The role of NF-kappaB/IkappaB proteins in cancer: implications for novel treatment strategies. Surg Oncol. 1999;8:143–53.CrossRefPubMed

42.

Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, Barnes DM, Gillett CE, Camplejohn R, Dover R, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 1990;162:285–94.CrossRefPubMed

43.

Rossi AGZ, Soares Jr JM, Motta ELA, Simões MJ, Oliveira-Filho RM, Haidar MA, Rodrigues de Lima G, Baracat EC. Metoclopramide-induced hyperprolactinemia affects mouse endometrial morphology. Gynecol Obstet Investig. 2003;54:185–90.CrossRef

44.

Schindelin J, Rueden CT, Hiner MC, Eliceiri KW. The ImageJ ecosystem: an open platform for biomedical image analysis. Mol Reprod Dev. 2015;82:518–29.CrossRefPubMedPubMedCentral

45.

Durlinger ALL, Gruijters MJG, Kramer P, Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JTJ, Grootegoed JA, Themmen APN. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology. 2001;142:4891–9.CrossRefPubMed

46.

Myers M, Britt KL, Wreford NGM, Ebling FJP, Kerr JB. Methods for quantifying follicular numbers within the mouse ovary. Reproduction. 2004;127:569–80.CrossRefPubMed

47.

Ray A, Dittel BN. Isolation of mouse peritoneal cavity cells. J Vis Exp. 2010:e1488.

48.

Grzechocinska B, Gadomska H, Zygula A, Wielgos M. Application of ulipristal acetate in female patients with uterine fibroids. Neuroendocrinol Lett. 2014;35:175–8.PubMed

49.

Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception. 2013;88:611–8.CrossRefPubMed

50.

Huniadi CA, Pop OL, Antal TA, Stamatian F. The effects of ulipristal on Bax/Bcl-2, cytochrome C, Ki-67 and cyclooxygenase-2 expression in a rat model with surgically induced endometriosis. Eur J Obstet Gynecol Reprod Biol. 2013;169:360–5.CrossRefPubMed

51.

Rossé T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B, Borner C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 1998;391:496–9.CrossRefPubMed

52.

Yoshino O, Osuga Y, Hirota Y, Koga K, Hirata T, Harada M, Morimoto C, Yano T, Nishii O, Tsutsumi O, Taketani Y. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis. Am J Reprod Immunol. 2004;52:306–11.CrossRefPubMed

53.

Schulze-Osthoff K, Ferrari D, Riehemann K, Wesselborg S. Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology. 1997;198:35–49.CrossRefPubMed

54.

Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;23:2838–49.CrossRefPubMed

55.

Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell. 2007;129:665–79.CrossRefPubMed

56.

Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMed

57.

Ylänen K, Laatikainen T, Lähteenmäki P, Moo-Young AJ. Subdermal progestin implant (Nestorone®) in the treatment of endometriosis: clinical response to various doses. Acta Obstet Gynecol Scand. 2003;82:167–72.PubMed

58.

Donnez J, Hudecek R, Donnez O, Matule D, Arhendt H-J, Zatik J, Kasilovskiene Z, Dumitrascu MC, Fernandez H, Barlow DH, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103:519–27. e513CrossRefPubMed

59.

Kim SA, Um MJ, Kim HK, Kim SJ, Moon SJ, Jung H. Study of dienogest for dysmenorrhea and pelvic pain associated with endometriosis. Obstet Gynecol Sci. 2016;59:506–11.CrossRefPubMedPubMedCentral

60.

Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25:633–41.CrossRefPubMed

61.

Berlanda N, Somigliana E, Frattaruolo MP, Buggio L, Dridi D, Vercellini P. Surgery versus hormonal therapy for deep endometriosis: is it a choice of the physician? Eur J Obstet Gynecol Reprod Biol. 2017;209:67–71.CrossRefPubMed

62.

Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev. 2005;26:423–38.CrossRefPubMed

63.

Arendas K, Leyland NA. Use of Ulipristal acetate for the Management of Fibroid-Related Acute Abnormal Uterine Bleeding. J Obstet Gynaecol Can. 2016;38:80–3.CrossRefPubMed

64.

Matytsina-Quinlan L, Matytsina L. Abnormal excessive per vagina (PV) bleeding on Esmya-selective progesterone receptor modulator (SPRM) in a symptomatic patient with uterine fibroid. BMJ Case Rep. 2015;2015:bcr2014209015.CrossRefPubMedPubMedCentral

65.

Nagata C, Yanagida S, Okamoto A, Morikawa A, Sugimoto K, Okamoto S, Ochiai K, Tanaka T. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest. J Obstet Gynaecol Res. 2012;38:639–44.CrossRefPubMed

66.

Micks EA, Jensen JT. Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill. Adv Ther. 2013;30:1–13.CrossRefPubMed

67.

Whitaker LHR, Murray AA, Matthews R, Shaw G, Williams ARW, Saunders PTK, Critchley HOD. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. Hum Reprod. 2017;32:531–43.PubMedPubMedCentral

68.

Jesam C, Cochon L, Salvatierra AM, Williams A, Kapp N, Levy-Gompel D, Brache V. A prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate. Contraception. 2016;93:310–6.CrossRefPubMed

69.

Nakamura S, Douchi T, Oki T, Ijuin H, Yamamoto S, Nagata Y. Relationship between sonographic endometrial thickness and progestin-induced withdrawal bleeding. Obstet Gynecol. 1996;87:722–5.CrossRefPubMed

70.

Bergeron C, Fox H. Low incidence of endometrial hyperplasia with acceptable bleeding patterns in women taking sequential hormone replacement therapy with dydrogesterone. Gynecol Endocrinol. 2000;14:275–81.CrossRefPubMed

71.

Quereux C, Pornel B, Bergeron C, Ferenczy A. Continuous combined hormone replacement therapy with 1 mg 17β-oestradiol and 5 mg dydrogesterone (Femoston®-conti): endometrial safety and bleeding profile. Maturitas. 2006;53:299–305.CrossRefPubMed

72.

Kodama M, Onoue M, Otsuka H, Yada-Hashimoto N, Saeki N, Kodama T, Wakasa T, Funato T. Efficacy of Dienogest in thinning the endometrium before Hysteroscopic surgery. J Minim Invasive Gynecol. 2013;20:790–5.CrossRefPubMed

73.

Laganà AS, Vitale SG, Muscia V, Rossetti P, Buscema M, Triolo O, Rapisarda AMC, Giunta L, Palmara V, Granese R, et al. Endometrial preparation with Dienogest before hysteroscopic surgery: a systematic review. Arch Gynecol Obstet. 2017;295:661–7.CrossRefPubMed

74.

Klipping C, Duijkers I, Remmers A, Faustmann T, Zurth C, Klein S, Schuett B. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol. 2012;52:1704–13.CrossRefPubMed

75.

Claassen V, Morsink L, de Wachter AM. Influence of dydrogesterone (6-dehydroretroprogesterone, Duphaston) on ovulation in the rat, rabbit and monkey. Acta Endocrinol. 1971;67:551–62.PubMed

76.

Endrikat J, Parke S, Trummer D, Serrani M, Duijkers I, Klipping C. Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study. Contraception. 2013;87:227–34.CrossRefPubMed

77.

Brache V, Cochon L, Jesam C, Maldonado R, Salvatierra AM, Levy DP, Gainer E, Croxatto HB. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod. 2010;25:2256–63.CrossRefPubMed

78.

Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15:441–61.CrossRefPubMed

79.

Signorile PG, Baldi A. New evidence in endometriosis. Int J Biochem Cell Biol. 2015;60:19–22.CrossRefPubMed

Title: Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice
Authors: Bo Liang
Ling Wu
Hui Xu
Chun Wai Cheung
Wen Ying Fung
Sze Wai Wong
Chi Chiu Wang
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Reproductive Biology and Endocrinology / Issue 1/2018
Electronic ISSN: 1477-7827
DOI: https://doi.org/10.1186/s12958-018-0347-9

ACC 2024 Congress

Springer Medicine

Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial

Analysis of human sperm DNA fragmentation index (DFI) related factors: a report of 1010 subfertile men in China

Role of L-carnitine in female infertility

Lactate promotes specific differentiation in bovine granulosa cells depending on lactate uptake thus mimicking an early post-LH stage

Frequency of the T307A, N680S, and -29G>A single-nucleotide polymorphisms in the follicle-stimulating hormone receptor in Mexican subjects of Hispanic ancestry

Maternal physical activity before IVF/ICSI cycles improves clinical pregnancy rate and live birth rate: a systematic review and meta-analysis